Bioleksp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-10-05
Share capital
435,000.00 PLN
Activity description

E-TECH s.c. provides IT consulting and IT implementations for public and private sector clients. The company handles IT infrastructure audits, solution selection, purchasing, delivery and installation of systems and hardware, plus post-warranty service. Its offer includes servers, disk arrays, switches / Wi‑Fi, workstations and client hardware.

Registered address
Poznańska 12, 05-850 Macierzysz, Poland
Website
biolek.com.pl
Email

Financials

Total Operating Costs
2.09m
+18.2% vs 2024

Revenue history (in m)

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 13 days late). All were audited by a statutory auditor.

  • 202503/07/2026
  • 202407/07/2025
  • 202326/06/2024
  • 202219/06/2023
  • 202128/07/2022
  • 202006/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 2.79mMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD 261.29kMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 2.09mMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 1.26mMedianUSD 883.09kAverageUSD 31.39m

Industry

Trademarks

Biolek holds 3 active trademarks registered with the Polish Patent Office. 3 marks have expired or were not registered. The first mark was filed in 2006.

MarkNumberClassesStatusProtected until
Laxibiom(word)Z.5628625Protected Nov 21, 2033
Intesta TempoZ.5503995Protected Dec 16, 2032
Intesta BiomZ.5503985Protected Dec 16, 2032
BIOLEKZ.3320405, 31, 35, 42Expired –
BUTYRGUT(word)Z.3207285Expired –
MarkProtected until
Laxibiom(word)Nov 21, 2033
Intesta TempoDec 16, 2032
Intesta BiomDec 16, 2032
BIOLEK–
BUTYRGUT(word)–

Authorized Representatives

Romuald Apollo Harwas – Management Board Member
Jeremy James Launders – Vice President of the Management Board
Mateusz Patryk Kosecki – President of the Management Board

Manner of representation

If the management board is a multi-member management board, the President of the Management Board acting jointly with another member of the management board or a commercial proxy, or the Vice-President acting jointly with another member of the management board or a commercial proxy, are authorised to submit declarations of will and sign on behalf of the company.

Ownership

OwnerSharesShare valueStake
Bioton S.A.
870$117,504.05100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2010-10-25.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Adamed PharmaS.A.
Anpharm Przedsiębiorstwo FarmaceutyczneS.A.
BiotonS.A.
Celon PharmaS.A.
VipharmS.A.
MedicofarmaS.A.
Munar PharmaS.A.
Sanford Biotechsp. z o.o.
Cefeasp. z o.o.
Auxilius PharmaS.A.

Change history

DateEvent
2018-01-10PKD change
2015-07-10PKD change
2012-08-16Address change
2011-11-29Address change
2011-07-26Share capital increase

FAQ

Last updated: 2026-10-07